Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Work In Process (2016 - 2025)

Historic Work In Process for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $2.3 million.

  • Harvard Bioscience's Work In Process fell 3500.43% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 3500.43%. This contributed to the annual value of $2.8 million for FY2024, which is 3424.07% down from last year.
  • Per Harvard Bioscience's latest filing, its Work In Process stood at $2.3 million for Q3 2025, which was down 3500.43% from $1.6 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Work In Process high stood at $4.6 million for Q3 2023, and its period low was $1.6 million during Q2 2025.
  • Moreover, its 5-year median value for Work In Process was $3.5 million (2021), whereas its average is $3.5 million.
  • Per our database at Business Quant, Harvard Bioscience's Work In Process surged by 2069.68% in 2023 and then tumbled by 5279.13% in 2025.
  • Over the past 5 years, Harvard Bioscience's Work In Process (Quarter) stood at $3.4 million in 2021, then increased by 10.73% to $3.8 million in 2022, then rose by 10.91% to $4.2 million in 2023, then tumbled by 34.24% to $2.8 million in 2024, then decreased by 18.08% to $2.3 million in 2025.
  • Its Work In Process stands at $2.3 million for Q3 2025, versus $1.6 million for Q2 2025 and $3.0 million for Q1 2025.